ArticleDrug and alcohol dependence2022
Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.
Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Integrated care van delivery of evidence-based services for people who inject drugs: A cluster-randomized trial.Addiction (Abingdon, England) · 2024Trial
- The Drug Market's Impact on the Overdose Risk Environment for Women Who Use Drugs During the COVID-19 Pandemic.Journal of urban health : bulletin of the New York Academy of Medicine · 2026Article
- Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025Review
- Mental health behaviors and suicide risk among White and Black adults with Opioid Use Disorder.Social science & medicine (1982) · 2025Article
- Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review.Journal of telemedicine and telecare · 2025Article
- Impact of COVID-19 on Substance Use Disorder Treatment: Examining the Influence of In-Person and Telehealth Intervention on Outcomes Using Real-World Data.Healthcare (Basel, Switzerland) · 2025Article
- What waiver? A qualitative exploration of awareness of the X-waiver among underserved patients and providers and the impact on tele-OUD services uptake.Frontiers in psychiatry · 2025Article
- Old tech but not low tech: telephone-based treatment provision for substance use.Frontiers in psychiatry · 2024Article
- Exploring the impact of the COVID-19 pandemic on healthcare and substance use service access among women who inject drugs: a qualitative study.Harm reduction journal · 2023Article
- Age-specific disparities in fatal drug overdoses highest among older black adults and American Indian/Alaska native individuals of all ages in the United States, 2015-2020.The International journal on drug policy · 2023Article
- The Use of Digital Health Services Among Patients and Citizens Living at Home: Scoping Review.Journal of medical Internet research · 2023Article
- Principal component regression analysis of familial psychiatric histories and suicide risk factors among adults with opioid use disorder.Journal of psychiatric research · 2023Article
- Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States.Drug and alcohol dependence · 2023Review
- "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.Harm reduction journal · 2022Article
- Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.JAMA network open · 2022Article
- The multiple uses of telemedicine during the pandemic: the evidence from a cross-sectional survey of medical doctors in Brazil.Globalization and health · 2022Article
- Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs.Substance abuse treatment, prevention, and policy · 2022Article
- Access to care through telehealth among U.S. Medicare beneficiaries in the wake of the COVID-19 pandemic.Frontiers in public health · 2022Article
- Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChanges in federal policy during the COVID-19 pandemic allowing for the use of telemedicine to treat opioid use disorder (OUD) have facilitated innovative strategies to engage and retain people in treatment. Since 2018, the Baltimore City Health Department has operated a mobile street medicine program called Healthcare on The Spot (The Spot) that provides treatment for OUD and infectious diseases. This study describes the transition of The Spot's buprenorphine service to telemedicine during the COVID-19 pandemic and one year treatment retention.
methodsPatients actively engaged in care at the time of transition to telemedicine and patients newly engaged in buprenorphine services through telemedicine were included in this descriptive analysis and assessed at one year for retention.
resultsFrom March 16, 2020 to March 15, 2021, The Spot provided voice-only buprenorphine treatment services to 150 patients, 70.7% (n = 106) male and 80.0% (n = 120) Black; 131 were patients who transitioned from in person services and 19 were newly engaged via telemedicine. 80.7% (n = 121) of patients remained engaged in treatment at one year, 16.0% (n = 24) were lost to follow-up, and 3.3% (n = 5) were deceased. Patients newly engaged via telemedicine were more likely to be female and white than those retained from in person services.
conclusionThe Spot's transition of patients from a street medicine program to telemedicine during the COVID-19 pandemic has implications for future practice. Increased flexibility of service delivery, extended prescription length, and decreased UDT likely contributed to high retention rates and should inform the future structure of low-threshold buprenorphine programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.